From Rep Visits to Reputation: How Bharat Bhushan Chawla Is Rewriting Pharma Marketing in India”
Walk into almost any doctor’s clinic in India and you will see the same scene. A waiting room full of patients, and a row of medical representatives waiting for their five minutes. Every company fights for the same attention with the same brochures and the same pitch. Bharat Bhushan Chawla, Marketing Head at Amneal Healthcare with 15 years of experience in pharma, believes this model is running out of road.
His question is a simple one: “What if the doctor already trusts you before the rep walks in?”
The Problem Nobody Talks About
Pharma marketing in India works within strict limits. Prescription medicines cannot be advertised to the public, and the rules on promotion to doctors keep getting tighter. Most companies responded by sending out more representatives and funding more events. The result is a crowded market where products with similar formulations look identical, and the loudest brand often beats the better one.
Bharat Bhushan Chawla noticed this early. Across his work with Pfizer, Novartis and Dr. Reddy’s Laboratories, he saw that doctors prescribed the names they had met repeatedly in credible places, not the names that were pushed hardest. Acting on that insight, he helped Eliquis grow its market share five times within six months at Pfizer. At Dr. Reddy’s, Atocor’s market share doubled in three months, and at Novartis, Xolair doubled in a year.
That was not luck. It was a method, and he has been refining it ever since.
The Three-Pillar Approach
Built on that insight, his approach rests on three pillars:
- Scientific Authority – Positioning a brand as a source of knowledge, through clinical content, doctor-led education, medical journal visibility and credible media features.
- Compliant Visibility – Being present where doctors actually spend their time, such as professional networks, CMEs, webinars and trusted publications, always within regulatory guidelines.
- Relationship Systems – Replacing one-off rep visits with structured follow-up, digital touchpoints and feedback loops that keep a brand in a doctor’s mind between meetings.
Together, these pillars move a company from pushing products to earning preference.
Changing How India Sees Rare Disease
Some of his most meaningful work has been in rare diseases, where patients often wait years for a correct diagnosis. Bharat Bhushan Chawla focused on early diagnosis and paired it with funding solutions, so that patients could get the right treatment on time. The shift in approach changed how the market looks at rare disease, and it delivered a fivefold revenue increase in 18 months.
His work on Ocrevus at Roche, where he handled the launch, earned the company a Gold award at the Healthscience Advancement Honours for the best launch in India.
A Name That Commands Respect
With 15 years of hands-on experience across Pfizer, Novartis, Roche, Dr. Reddy’s Laboratories and now Amneal Healthcare, Bharat Bhushan Chawla brings both multinational discipline and an understanding of the Indian market. What sets him apart is his approach. He is known for plain talk in an industry full of jargon. He does not promise shortcuts, because in healthcare trust cannot be rushed and compliance cannot be skipped.
The Message That Is Resonating
India’s healthcare sector is growing fast, and so is the competition for every doctor’s attention. Brands that rely only on old methods will find it harder each year. Those that build authority, stay compliant and keep showing up with real value will win the long game.
“Doctors don’t prescribe the brand that shouts the loudest,” Bharat Bhushan Chawla says. “They prescribe the one they know, understand and trust.”
His advice to marketers is direct: “Stop asking how to reach more doctors. Start asking why a doctor should remember you.”
